Anti-Signal Recognition Particle-Positive Immune-Mediated Necrotizing Myopathy with Acute Inpatient Myocarditis and Pharyngeal Involvement in a Young Adult: A Case Highlighting the Importance of Early Biologic Escalation – A Case Report
This case report describes a young Indian woman with severe, steroid-resistant anti-SRP-positive immune-mediated necrotizing myopathy complicated by acute myocarditis and pharyngeal involvement, whose recovery was achieved only through timely biologic escalation with pulse steroids, IVIg, and rituximab, thereby underscoring the critical need for early aggressive treatment and proactive cardiac surveillance in this aggressive disease phenotype.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human body's immune system is designed to act as a vigilant defense force, identifying and neutralizing foreign invaders like viruses and bacteria. However, sometimes this system malfunctions, turning its weapons against the body's own tissues. When this happens in the muscles, it leads to a group of conditions known as inflammatory myopathies. In most cases, the immune system attacks by sending in a swarm of inflammatory cells that invade the muscle tissue. But there is a rarer, more aggressive form where the damage is caused differently: the immune system triggers a direct chemical breakdown of the muscle fibers, causing them to die and dissolve without the usual heavy presence of invading cells. This specific condition is called immune-mediated necrotizing myopathy. While doctors have learned to recognize the signs of muscle weakness and high levels of muscle enzymes in the blood, they are still working to understand how this disease behaves in its most severe forms, particularly when it strikes young people and spreads to vital organs like the heart.
A recent case report from India brings this complex picture into sharp focus, detailing the journey of a twenty-six-year-old woman who arrived at the hospital with a terrifying and rapidly worsening decline in her physical strength. For two months, she had experienced a slow, symmetric loss of power in her shoulders and hips, making it difficult to lift her arms or walk. Over the next month, the weakness spread to her trunk, and ten days before her admission, she developed difficulty swallowing. When she finally reached the emergency department, she was unable to walk without assistance and could not swallow water. Her blood tests revealed a massive release of muscle enzymes, with a specific marker called creatine kinase reaching nearly six thousand units per liter, a level far exceeding the normal range and indicating severe muscle destruction.
Initial testing confirmed that her immune system was producing a specific antibody known as anti-signal recognition particle, or anti-SRP. This antibody targets a tiny machine inside cells that helps build proteins, and its presence defines a particularly aggressive subtype of the disease. The medical team also found that she had other antibodies typically associated with a different condition called Sjögren's syndrome, but she lacked the classic symptoms of dry eyes and dry mouth, leading doctors to conclude she did not have that specific disease. A biopsy of her thigh muscle, a procedure where a small sample is taken for examination, showed the hallmark signs of this rare condition: muscle fibers that were dying and being eaten away by the body's cleanup cells, with a notable absence of the inflammatory cells usually seen in other muscle diseases.
Despite starting the patient on standard treatments for muscle inflammation, including high doses of steroids and a drug called methotrexate, her condition continued to deteriorate. Within days, she lost the ability to walk entirely and her swallowing difficulties became complete. The situation took a critical turn on the eighth day of her hospital stay when she began experiencing heart palpitations and chest discomfort. An electrocardiogram showed a dangerously slow heart rate and unusual changes in the electrical pattern of her heart, while a blood test for a heart protein called troponin T came back positive. Although an ultrasound of her heart showed that the pumping function was still normal, the combination of new heart rhythm problems, the positive blood test, and the ongoing immune storm suggested she was developing inflammation of the heart muscle itself. This was a rare complication, appearing not as the first sign of the disease but as a sudden, life-threatening development during her hospitalization.
The medical team realized that the standard approach was not working and needed to escalate their strategy quickly. They administered a powerful pulse of intravenous steroids to try to calm the immune system, followed by a course of intravenous immunoglobulin, which is a treatment made from donated blood that helps reset the immune response. These measures helped stabilize her heart and improve her ability to swallow, but her muscle weakness remained severe. The turning point came when the doctors introduced a biologic therapy called rituximab, a medication designed to specifically target and remove the B-cells that produce the harmful antibodies. After the first dose, the patient's recovery began almost immediately. Within three days, she could walk with minimal support, and her blood levels of muscle enzymes, which had peaked at over seven thousand units per liter, began to plummet. By the twenty-third day, her enzyme levels had returned to near-normal, and her muscle strength had improved dramatically.
This case highlights several critical lessons for understanding this severe form of muscle disease. First, it demonstrates that anti-SRP myopathy can strike young adults and progress with alarming speed, often failing to respond to standard steroid treatments. Second, it underscores the danger of the disease spreading to the heart, a complication that can occur even after the initial diagnosis and requires close monitoring. The doctors also noted a diagnostic challenge: the blood test for heart damage, troponin T, can sometimes give a false alarm in patients with severe muscle disease because the same protein can be released from damaged skeletal muscles. In this patient, the heart ultrasound remained normal, suggesting the heart damage was likely mild or inflammatory rather than a massive heart attack, but the event served as a stark reminder of the systemic nature of the illness.
The patient's eventual recovery to a state where she could perform daily activities and had nearly full muscle strength was achieved only through the timely addition of rituximab. Her experience supports the growing medical consensus that for patients with this specific antibody profile, waiting to see if standard drugs work can be dangerous. Instead, early escalation to powerful biologic therapies may be necessary to prevent permanent disability or life-threatening organ damage. The report concludes that while the path to recovery can be long and complex, recognizing the unique features of this disease and acting quickly with the right treatments can lead to a full return of health, even in the most severe cases.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.